QIAGEN

QIAGEN NV is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The firm automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D, and industrial applications, primarily forensics). The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QIAGEN surpasses 2022 targets, eyes growth in diagnostics and biopharma

QIAGEN's strong performance in 2022 exceeded expectations, supported by robust financials and strategic acquisitions.
Despite market challenges, the company remains confident in achieving its 2023 targets, focusing on growth opportunities in diagnostics and biopharma.
Emphasis on innovation, customer knowledge, and strategic shifts position QIAGEN well for sustained growth and leadership in the industry.

QIAGEN surpasses Q1 sales targets, eyes China growth opportunities

QIAGEN's Q1 2023 performance exceeded expectations, with strong sales growth and margin improvements.
The company remains focused on driving growth through product innovation and strategic market expansion.
Challenges include cautious customer spending and evolving market dynamics, particularly in China.
Opportunities lie in capitalizing on strong product performance, investing in new solutions, and expanding market reach.

QIAGEN reports strong Q2 earnings, eyes China growth opportunities

QIAGEN's Q2 performance was solid, driven by key growth areas, but challenges persist with net sales decline and market volatility. The company's strengths in base business sales and focus on growth pillars position it well for future opportunities in China and market expansion.

QIAGEN surpasses Q3 expectations, focuses on sustained growth strategies

QIAGEN's Q3 2023 performance exceeded expectations, showcasing strong financials and strategic leadership changes, with a reaffirmed full-year outlook for 2023.
The company's strengths lie in successful product pillars, sustained growth strategies, and a strategic focus on non-COVID products in key markets.
Challenges include debt repayment impacts, external market uncertainties, and competitive differentiation in expanding product offerings, while opportunities exist in market expansion, innovation, and automation investments.

QIAGEN surpasses Q4 expectations, eyes strategic growth opportunities

QIAGEN's Q4 performance exceeded expectations, showcasing strong growth and profitability.
Challenges include potential risks in Q1 and delays impacting certain product growth.
Strategic investments and upcoming launches present opportunities for continued growth and market expansion.
Overall, QIAGEN's focus on innovation and strategic acquisitions positions them for sustained success in the future.

QIAGEN beats Q1 sales targets, eyes FDA approvals for growth

QIAGEN's Q1 2024 performance exceeded expectations, with strong sales in Diagnostic Solutions. The company reaffirmed its full-year outlook and highlighted advancements in its product portfolio. Despite challenges in the Chinese market, QIAGEN remains focused on growth opportunities and efficient capital allocation.

QIAGEN surpasses Q3 expectations, boosts outlook amid leadership change

QIAGEN delivered strong Q3 results, surpassing expectations and demonstrating improved profitability. Despite leadership changes, the company's strategic initiatives and global positioning bode well for future growth and resilience in the face of market dynamics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Hologic

Owens & Minor

Here we look at three stocks, OMI, HOLX and QGEN, that investors can add to their watchlist backed by robust long-term prospects.

3 GARP MedTech Stocks to Snap Up Despite Pandemic Woes

QIAGEN's (QGEN) latest kit is likely to significantly reduce library turnaround times and plastics usage, thus allowing more accurate detection and quantification of molecular variants.

QIAGEN (QGEN) Launches QIAseq Kit, Enhances COVID-19 Portfolio

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN adds to COVID-19 portfolio with new ultra-fast sequencing solution for high-throughput genomic surveillance

QIAGEN Adds to COVID-19 Portfolio With New Ultra-Fast Sequencing Solution for High-Throughput Genomic Surveillance

QIAGEN's (QGEN) new NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage test strengthens the company's portfolio in PCR testing, while becoming a crucial diagnostic tool for the flu season and the pandemic.

QIAGEN's (QGEN) NeuMoDx Multiplex Test Receives FDA EUA

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN receives FDA Emergency Use Authorization for NeuMoDx multiplex test expanding COVID-19 portfolio

QIAGEN Receives FDA Emergency Use Authorization for NeuMoDx Multiplex Test Expanding COVID-19 Portfolio

QIAGEN (QGEN) expands specimen types that can be used on the existing NeuMoDx SARSCoV-2 test.

QIAGEN (QGEN) Rides on Test Launches Amid COVID-19 Woes

QIAGEN's (QGEN) QIAsphere cloud-based platform will enhance QIAstat-Dx's potential by offering remote services round the clock to improve testing continuity.

QIAGEN (QGEN) Unveils Digital Platform for Syndromic Testing

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN announces 20-F annual report filing for 2020 results

QIAGEN Announces 20-F Annual Report Filing for 2020 Results

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN--QIAGEN launches QIAsphere cloud-based connectivity solution to enhance QIAstat-Dx capabilities in digital diagnostics

QIAGEN Launches QIAsphere Cloud-Based Connectivity Solution to Enhance QIAstat-Dx Capabilities in Digital Diagnostics

QIAGEN's (QGEN) QIAcube Connect MDx platform can be used with more than 140 standard protocols and it ensures complete consistency of the purification of multiple sample types.

QIAGEN (QGEN) Launches QIAcube Connect MDx Platform Globally

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN launches QIAcube Connect MDx platform for automated sample processing in diagnostic labs

QIAGEN Launches QIAcube Connect MDx Platform for Automated Sample Processing in Diagnostic Labs

Inovio Pharmaceuticals

Qiagen NV (NYSE: QGEN) and Inovio Pharmaceuticals Inc (NASDAQ: INO) expanded their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products using next-generation sequencing technology to complement Inovio's therapies. The initial project in this expanded collaboration focuses on the co-development of a diagnostic test that identifies women who are most likely to benefit from the clinical use of VGX-3100, INO's immunotherapy, to treat advanced cervical dysplasia associated with the human papillomavirus (HPV).

Qiagen, Inovio In Development Pact For VGX-3100 Companion Diagnostics

PLYMOUTH MEETING, Pa. & GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN and INOVIO expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100

QIAGEN and INOVIO Expand Collaboration to Develop Next Generation Sequencing (NGS) Companion Diagnostic for INOVIO's VGX-3100 for Advanced Cervical Dysplasia

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN expands Supervisory Board with appointment of a new member

QIAGEN Expands Supervisory Board With Appointment of a New Member

QIAGEN N.V. (QGEN) CEO Thierry Bernard on Q4 2020 Results - Earnings Call Transcript

QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.

QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Improve

Qiagen (QGEN) delivered earnings and revenue surprises of 3.03% and 3.51%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Beats Q4 Earnings and Revenue Estimates

Shares of Qiagen (NYSE:QGEN) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 41.67% year over year to $0.68, which beat the estimate of $0.65.

Recap: Qiagen Q4 Earnings

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN beats outlook for fourth quarter and full-year 2020, reaffirms expectations for further growth in 2021

QIAGEN Beats Outlook for Fourth Quarter and Full-Year 2020, Reaffirms Expectations for Further Growth in 2021

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN adds dPCR platform QIAcuity to growing portfolio of COVID-19 testing solutions for wastewater and mutation testing

QIAGEN Adds dPCR Platform QIAcuity to Growing Portfolio of COVID-19 Testing Solutions for Wastewater and Mutation Testing

QIAGEN (QGEN) along with with Australia-based digital diagnostics company, Ellume develops QIAreach SARS-CoV-2 Antigen Test.

QIAGEN (QGEN) Announces COVID-19 Test Updates as Cases Rise

VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. to Report Fourth Quarter and Full-Year 2020 Results

QIAGEN N.V. to Report Fourth Quarter and Full-Year 2020 Results

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN plans to resubmit EUA submission in the U.S. for QIAreach SARS-CoV-2 Antigen Test in the first quarter of 2021

QIAGEN Plans to Resubmit EUA Submission in the U.S. for QIAreach SARS-CoV-2 Antigen Test in the First Quarter of 2021

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN confirms effectiveness of its SARS-CoV-2 PCR tests in the face of mutations of the coronavirus

News for QIAGEN Stock (QGEN)